![]() |
Volumn 109, Issue 4, 2002, Pages 489-502
|
A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa
a
|
Author keywords
Bromocriptine; Drug therapy; Parkinson's disease; Ropinirole
|
Indexed keywords
AMANTADINE;
BROMOCRIPTINE;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
DOMPERIDONE;
DOPAMINE RECEPTOR STIMULATING AGENT;
LEVODOPA;
ROPINIROLE;
SELEGILINE;
ADULT;
AGED;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
DRUG TOLERABILITY;
DYSKINESIA;
FEMALE;
HALLUCINATION;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NAUSEA;
PARKINSON DISEASE;
PARKINSONISM;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SAMPLE SIZE;
TITRIMETRY;
TREATMENT OUTCOME;
VERTIGO;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTIPARKINSON AGENTS;
BROMOCRIPTINE;
DOUBLE-BLIND METHOD;
DRUG THERAPY, COMBINATION;
DYSKINESIA, DRUG-INDUCED;
FEMALE;
HALLUCINATIONS;
HUMANS;
INDOLES;
LEVODOPA;
LOGISTIC MODELS;
MALE;
MIDDLE AGED;
ODDS RATIO;
PARKINSON DISEASE;
|
EID: 0036209516
PISSN: 03009564
EISSN: None
Source Type: Journal
DOI: 10.1007/s007020200040 Document Type: Article |
Times cited : (61)
|
References (32)
|